Boditech Med Inc. (KOSDAQ:206640)
 13,570
 -20 (-0.15%)
  Oct 31, 2025, 3:30 PM KST
Boditech Med Revenue
Boditech Med had revenue of 41.48B KRW in the quarter ending June 30, 2025, with 14.44% growth. This brings the company's revenue in the last twelve months to 149.40B, up 7.38% year-over-year. In the year 2024, Boditech Med had annual revenue of 138.16B with 2.94% growth.
Revenue (ttm) 
 149.40B
Revenue Growth 
 +7.38%
P/S Ratio 
 1.98
Revenue / Employee 
 276.15M
Employees 
 541
Market Cap 
296.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 138.16B | 3.94B | 2.94% | 
| Dec 31, 2023 | 134.22B | 16.14B | 13.67% | 
| Dec 31, 2022 | 118.08B | -39.63B | -25.13% | 
| Dec 31, 2021 | 157.71B | 13.58B | 9.42% | 
| Dec 31, 2020 | 144.13B | 71.33B | 97.99% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |